NorthRock Partners’s Adial Pharmaceuticals ADIL Stock Holding History

NorthRock Partners’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-16	Closed	-$43K	–	338
2021 Q3	$43K	Buy	+16	New	+$33.5K	﹤0.01%	279

Other funds holding ADIL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

NorthRock Partners's ADIL Position: Q4 2021 in Review

NorthRock Partners sold out of Adial Pharmaceuticals (ADIL) in Q4 2021, closing a stake of 16 shares — an estimated $43K sold.

NorthRock Partners first reported a position in ADIL in Q3 2021 and held it in 1 quarter. The position peaked at $43K in Q3 2021. 22 funds tracked by Wall St. Rank hold ADIL as of Q4 2021.

NorthRock Partners reported no remaining Adial Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
NorthRock Partners sold 16 Adial Pharmaceuticals shares in Q4 2021, an estimated $43K.
NorthRock Partners first reported a position in Adial Pharmaceuticals in Q3 2021 and held it in 1 quarter.
NorthRock Partners's Adial Pharmaceuticals position peaked at $43K in Q3 2021.
22 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q4 2021.

Based on NorthRock Partners's 13F filing for Q4 2021, filed 7 Feb 2022.